3037.TW (3037.TW)

$777.1B
Market Cap
113.7
P/E Ratio
1.65
Beta
0.29%
Dividend Yield
Piotroski 7/9Altman Z 4.2 SafeROIC−WACC -10.1%

Quantitative Summary

Deterministic

Financial health metrics are strong: Piotroski 7/9, Altman Z 4.2 (above 3.0 safe zone threshold).

Generated deterministically from quant metrics and financial statements. Not a recommendation.

Algorithmic Teardown

AI-Generated

The fundamental economics present a stark divergence between operational efficiency and capital allocation effectiveness. While the DuPont decomposition highlights robust revenue growth of 13.8% underpinning a net margin of 5.1%, the return on invested capital stands at merely 4.3%. This figure is critically undermined by a weighted average cost of capital (WACC) of 14.4%, resulting in a negative ROIC-WACC spread of -10.1%; this indicates that the business is currently destroying value for shareholders despite its top-line expansion velocity. Qualitative financial health metrics offer some reassurance, with a Piotroski F-Score of 7/9 signaling strong balance sheet stability and an Altman Z-Score of 4.2 suggesting low default risk, yet these defensive scores cannot offset the structural inefficiency where returns on capital fall significantly short of the cost to provide that capital.

Valuation metrics reflect extreme market optimism disconnected from the underlying return profile. The current price-to-earnings ratio of 113.7x is anomalously high relative to a company generating only modest net margins and negative economic value added, implying the market is pricing in sustained hyper-growth or an imminent transformation in capital efficiency that has not yet materialized. A standard discounted cash flow framework would likely reveal severe overvaluation given that future free cash flows must compound at rates far exceeding the 14.4% hurdle rate to justify such a premium multiple; instead, any short-term earnings miss could trigger a rapid re-rating as the disconnect between valuation and negative spread becomes undeniable.

The risk-reward profile is skewed heavily toward downside volatility due to the fragility of the current capital structure. Although insider activity or specific Fama-French alpha data are not provided in this dataset, the combination of high leverage implied by the need for such elevated multiples against a weak ROIC creates significant sensitivity to interest rate fluctuations and margin compression. The stock appears priced as if it possesses growth characteristics inconsistent with its actual cost of capital, leaving little room for error before multiple contraction forces align valuation with fundamentals.

Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.

Price Chart with Moving Averages

Loading chart...
SMA 50 SMA 200

Quant Health Deep Dive

7/9
Piotroski F-Score
Strong — high operational efficiency and profitability signals
4.2
Altman Z-Score
Safe Zone — above 3.0 threshold per academic model. Thresholds: >3 safe, 1.8–3 grey, <1.8 distress.

Profitability & Value Creation

13.9%
Gross Margin
5.1%
Net Margin
4.3%
ROIC
14.4%
WACC
ROIC − WACC Spread: -10.1%— Negative spread.
+13.8%
Revenue Growth (YoY)
+31.3%
Earnings Growth (YoY)
-11.1B
Free Cash Flow

Balance Sheet Health

1.39x
Debt / Equity
1.40x
Current Ratio
9.0x
Interest Coverage
-0.7x
Net Debt / EBITDA
-1.46%
FCF Yield
28.7B
EBITDA

Earnings Surprise History

Q4
✗ Miss
Est: $0.67
Act: $0.60
-10.4%
Q3
✗ Miss
Est: $0.68
Act: $0.62
-9.3%
Q2
✓ Beat
Est: $1.35
Act: $1.43
+5.7%
Q1
✓ Beat
Est: $1.54
Act: $2.29
+48.9%

EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.

Underwater (Drawdown from Peak)

How far below the all-time high the price has been over time. Deeper = more pain for holders.

Loading drawdown chart...

Rolling 60-Day Beta vs S&P 500 (VOO)

How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.

Loading beta chart...
Rolling Beta Market (β = 1.0)

Fundamentals

23.8
Forward P/E
PEG Ratio
7.50
Price/Book
45M
Avg Volume
$594.00
52W High
$70.40
52W Low
52W Range Position

ETF Contagion Visualizer

Simulate a price drop in 3037.TW to visualize passive redemption contagion across ETFs and collateral stocks.

3037.TW Shock
-0%
Est. Passive Redemption
$0
Systemic Risk
STABLE
3037.TWEpicenterEWTETF2330.TWLow Risk2308.TWLow Risk2454.TWLow Risk2317.TWMed Risk2383.TWLow Risk
3037.TW Price Drop (%)0

If 3037.TW (3037.TW) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies Taiwan Semiconductor Manufacturing Co Ltd (2330.TW) as the most exposed collateral stock, sharing 1 ETFs with 3037.TW. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.

Contagion model based on shared ETF exposure and constituent weights across 1 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.

3037.TW Ownership Dynamics

Ticker
3037.TW

ETFs with Highest 3037.TW Exposure

Float lock-up computed from 0 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).

3037.TW Capital Efficiency

How efficiently does 3037.TW convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.

Free Cash Flow
$-11,088,796,000
EBITDA
$28.7B
FCF Conversion
-39%
Reinvestment Rate
139%
-39% of EBITDA → Free Cash
0% (cash burn)25% (low)50% (efficient)100% (pure cash)
ROIC
4.3%
ROIC − WACC Spread
-10.1%

3037.TW converts -39% of its EBITDA into free cash flow, negative FCF conversion — the company is consuming cash faster than it generates EBITDA, which is unsustainable long-term. The 139% reinvestment rate signals aggressive capacity expansion. However, the ROIC-WACC spread is negative (-10.1%), suggesting reinvested capital is destroying shareholder value.

Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.

Compare 3037.TW to Peers

Quant metrics computed deterministically from financial statements and price data. Updated: N/A.

SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.